You are here

VLP BIOTECH, INC.

Company Information
Address 3210 MERRYFIELD ROW
San Diego, CA, 92121-1126


Information

DUNS: 160242579

# of Employees: 5


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A therapeutic vaccine for chronic hepatitis B

    Amount: $878,409.00

    Project Summary AbstractAlthough a safe and efficacious preventative vaccine for HBV has been available foryearsit is not effective against chronic infectionThe primary cause of chronic HBVCHBand the ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  2. An epitope-focused nanoparticle vaccine for anthrax

    Amount: $300,000.00

    Abstract We have successfully developed a highly immunogenicoptimized and lyophilizable epitope focusedbivalent anthrax vaccinereferred to as LND LF VLPusing our novel proprietary platform technology ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. A method to determine mRNA isoform frequencies using novel primer generators

    Amount: $225,000.00

    AbstractCurrent methods for RNA seq library preparation attempt to uniformly sample all sequences across every mRNA moleculeoptimally with sufficient overlap to allow de novo reassembly of the mRNA se ...

    SBIRPhase I2018Department of Health and Human Services
  4. An epitope focused nanoparticle vaccine for MRSA and biodefense

    Amount: $546,129.00

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  5. An Epitope-Focused Pediatric RSV Vaccine

    Amount: $224,141.00

    DESCRIPTION provided by applicant Although respiratory syncytial virus RSV infection occurs in of infants during the first year of life and are infected one or more times by year repr ...

    SBIRPhase I2016Department of Health and Human Services
  6. A molecularly targeted pre- and post-exposure vaccine for anthrax

    Amount: $509,817.00

    DESCRIPTION provided by applicant We have shown that immunization of rabbits with multiple antigenic peptides MAPs displaying sequence from domain of protective antigen PA elicit antibodies s ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
  7. A Therapeutic Vaccine for Chronic Hepatitis B

    Amount: $2,890,322.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to assess the feasibility of using recombinant virus-like- particles (VLPs) to elicit neutralizing antibodies and prime CD4+ T c ...

    SBIRPhase II2012Department of Health and Human Services
  8. A Therapeutic Vaccine for Chronic Hepatitis B

    Amount: $599,513.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to assess the feasibility of using recombinant virus-like-particles (VLPs) to elicit neutralizing antibodies and prime CD4+/CD8+ ...

    SBIRPhase I2010Department of Health and Human Services
  9. Development of a Proplylactic HCV Vaccine

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): The overall objective is to develop hepatitis C virus (HCV)-specific immunogens that may be useful as vaccines for the prevention of chronic HCV infection. In the ...

    SBIRPhase I2007Department of Health and Human Services
US Flag An Official Website of the United States Government